Business Description
NeuroOne Medical Technologies Corp
NAICS : 339113
SIC : 5047
ISIN : US64130M2098
Total Employee Number:
18Description
NeuroOne Medical Technologies Corp is focused on diagnostic, ablation, and deep brain stimulation technology for brain-related conditions such as epilepsy and Parkinson's disease; ablation and stimulation for pain management; and drug delivery with diagnostic and stimulation capabilities. It develops thin film electrode technology for various recording and therapeutic applications, crucial for diagnosing neurological disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors. The company operates in one segment, developing and commercializing products for neuromodulation, cEEG, and sEEG recording, monitoring, ablation, and brain stimulation, with revenue from Evo Cortical, Evo sEEG, and OneRF Ablation System.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 13.55 | |||||
Equity-to-Asset | 0.68 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | -0.03 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -8.38 | |||||
Beneish M-Score | 1.52 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 177 | |||||
3-Year EBITDA Growth Rate | 50.5 | |||||
3-Year EPS without NRI Growth Rate | 44.2 | |||||
3-Year FCF Growth Rate | 47 | |||||
3-Year Book Growth Rate | -37.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 48.49 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 34.25 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 50.99 | |||||
9-Day RSI | 42.88 | |||||
14-Day RSI | 39.92 | |||||
3-1 Month Momentum % | -15.15 | |||||
6-1 Month Momentum % | -11.61 | |||||
12-1 Month Momentum % | -11.64 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.38 | |||||
Quick Ratio | 3.28 | |||||
Cash Ratio | 1.66 | |||||
Days Inventory | 156.71 | |||||
Days Sales Outstanding | 62.64 | |||||
Days Payable | 63.97 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -45.5 | |||||
Shareholder Yield % | 0.42 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 54.51 | |||||
Operating Margin % | -72.69 | |||||
Net Margin % | -68.35 | |||||
EBITDA Margin % | -65.61 | |||||
FCF Margin % | -77.87 | |||||
OCF Margin % | -76.48 | |||||
ROE % | -118 | |||||
ROA % | -78.16 | |||||
ROIC % | -284.35 | |||||
3-Year ROIIC % | -3922.3 | |||||
ROC (Joel Greenblatt) % | -273.41 | |||||
ROCE % | -97.38 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 2.83 | |||||
PB Ratio | 5.29 | |||||
Price-to-Tangible-Book | 5.32 | |||||
EV-to-EBIT | -3.94 | |||||
EV-to-EBITDA | -4.1 | |||||
EV-to-Revenue | 2.69 | |||||
EV-to-Forward-Revenue | 4.1 | |||||
EV-to-FCF | -3.45 | |||||
Price-to-GF-Value | 0.5 | |||||
| Price-to-Net-Current-Asset-Value | 5.79 | |||||
| Price-to-Net-Cash | 82.5 | |||||
Earnings Yield (Greenblatt) % | -25.38 | |||||
FCF Yield % | -26.36 |
NeuroOne Medical Technologies Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
NeuroOne Medical Technologies Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2026-12-17 08:30 | In 174 days | ||
| Annual report for 2026 | 2026-12-17 | In 173 days | ||
| Fourth quarter earnings results for 2026 | 2026-12-17 | In 173 days | ||
| Third quarter earnings conference call for 2026 | 2026-08-14 08:30 | In 49 days | ||
| Third quarter earnings results for 2026 | 2026-08-14 | In 48 days | ||
| Guidance call for 2026 | 2026-06-17 15:00 | 3.25 (-3.27%) | ||
| Second quarter earnings conference call for 2026 | 2026-05-12 08:30 | 4.33 (-8.65%) | ||
| Second quarter earnings results for 2026 | 2026-05-12 | 4.33 (-8.65%) | ||
| 0.166667:1 Stock Split | 2026-04-16 | 4.44 (+4.24%) | ||
| General meeting for 2026 | 2026-04-03 09:00 | 4.77 (-2.93%) |
Show
Entries
Guru Commentaries on NAS:NMTC
No articles.
Press Release
Articles on NeuroOne Medical Technologies Corp
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers